Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 240

1.

Clinical features of LRRK2-associated Parkinson's disease in central Norway.

Aasly JO, Toft M, Fernandez-Mata I, Kachergus J, Hulihan M, White LR, Farrer M.

Ann Neurol. 2005 May;57(5):762-5.

PMID:
15852371
2.

A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.

Illarioshkin SN, Shadrina MI, Slominsky PA, Bespalova EV, Zagorovskaya TB, Bagyeva GKh, Markova ED, Limborska SA, Ivanova-Smolenskaya IA.

Eur J Neurol. 2007 Apr;14(4):413-7.

PMID:
17388990
3.

[Clinical features of LRRK2-associated Parkinson's disease].

Pchelina SN, Ivanova ON, Emel'ianov AK, Iakimovskiĭ AF.

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(12):56-62. Russian.

PMID:
22433811
4.

The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: clinical and demographic characteristics.

Gatto EM, Parisi V, Converso DP, Poderoso JJ, Carreras MC, Martí-Massó JF, Paisán-Ruiz C.

Neurosci Lett. 2013 Mar 14;537:1-5. doi: 10.1016/j.neulet.2013.01.011. Epub 2013 Jan 20.

PMID:
23340200
5.

LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease.

Infante J, Rodríguez E, Combarros O, Mateo I, Fontalba A, Pascual J, Oterino A, Polo JM, Leno C, Berciano J.

Neurosci Lett. 2006 Mar 13;395(3):224-6. Epub 2005 Nov 18.

PMID:
16298482
6.

Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD.

Gosal D, Ross OA, Wiley J, Irvine GB, Johnston JA, Toft M, Mata IF, Kachergus J, Hulihan M, Taylor JP, Lincoln SJ, Farrer MJ, Lynch T, Mark Gibson J.

Parkinsonism Relat Disord. 2005 Sep;11(6):349-52.

PMID:
16102999
7.

A study of LRRK2 mutations and Parkinson's disease in Brazil.

Pimentel MM, Moura KC, Abdalla CB, Pereira JS, de Rosso AL, Nicaretta DH, Campos M Jr, de Almeida RM, dos Santos JM, Bastos IC, Mendes MF, Maultasch H, Costa FH, Werneck AL, Santos-Rebouças CB.

Neurosci Lett. 2008 Mar 5;433(1):17-21. doi: 10.1016/j.neulet.2007.12.033. Epub 2007 Dec 23.

PMID:
18201824
8.

Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data.

Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M, Gibbons V, Gandhi S, Vaughan J, Eunson LH, Katzenschlager R, Gayton J, Lennox G, Revesz T, Nicholl D, Bhatia KP, Quinn N, Brooks D, Lees AJ, Davis MB, Piccini P, Singleton AB, Wood NW.

Brain. 2005 Dec;128(Pt 12):2786-96. Epub 2005 Nov 4.

PMID:
16272164
9.

Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.

Yahalom G, Kaplan N, Vituri A, Cohen OS, Inzelberg R, Kozlova E, Korczyn AD, Rosset S, Friedman E, Hassin-Baer S.

Parkinsonism Relat Disord. 2012 Nov;18(9):1039-41. doi: 10.1016/j.parkreldis.2012.05.014. Epub 2012 Jun 13.

PMID:
22703868
10.

[A PARK8 form of Parkinson's disease: a mutational analysis of the LRRK2 gene in Russian population].

Shadrina MI, Illarioshkin SN, Bagyeva GKh, Bespalova EV, Zagorodskaia TB, Slominskiĭ PA, Markova ED, Kliushnikov SA, Limborskaia SA, Ivanova-Smolenskaia IA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2007;107(3):46-50. Russian.

PMID:
18379513
11.

Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries.

Tomiyama H, Li Y, Funayama M, Hasegawa K, Yoshino H, Kubo S, Sato K, Hattori T, Lu CS, Inzelberg R, Djaldetti R, Melamed E, Amouri R, Gouider-Khouja N, Hentati F, Hatano Y, Wang M, Imamichi Y, Mizoguchi K, Miyajima H, Obata F, Toda T, Farrer MJ, Mizuno Y, Hattori N.

Mov Disord. 2006 Aug;21(8):1102-8.

PMID:
16622854
12.

Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.

Alcalay RN, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Kisselev S, Ross BM, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Caccappolo E, Ottman R, Clark LN, Marder KS.

Arch Neurol. 2009 Dec;66(12):1517-22. doi: 10.1001/archneurol.2009.267.

13.

The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor.

Goldwurm S, Di Fonzo A, Simons EJ, Rohé CF, Zini M, Canesi M, Tesei S, Zecchinelli A, Antonini A, Mariani C, Meucci N, Sacilotto G, Sironi F, Salani G, Ferreira J, Chien HF, Fabrizio E, Vanacore N, Dalla Libera A, Stocchi F, Diroma C, Lamberti P, Sampaio C, Meco G, Barbosa E, Bertoli-Avella AM, Breedveld GJ, Oostra BA, Pezzoli G, Bonifati V.

J Med Genet. 2005 Nov;42(11):e65.

14.

LRRK2 and Parkinson's disease in Norway.

Toft M, Haugarvoll K, Ross OA, Farrer MJ, Aasly JO.

Acta Neurol Scand Suppl. 2007;187:72-5.

PMID:
17419834
15.

DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study.

Trinh J, Gustavsson EK, Vilariño-Güell C, Bortnick S, Latourelle J, McKenzie MB, Tu CS, Nosova E, Khinda J, Milnerwood A, Lesage S, Brice A, Tazir M, Aasly JO, Parkkinen L, Haytural H, Foroud T, Myers RH, Sassi SB, Hentati E, Nabli F, Farhat E, Amouri R, Hentati F, Farrer MJ.

Lancet Neurol. 2016 Nov;15(12):1248-1256. doi: 10.1016/S1474-4422(16)30203-4. Epub 2016 Sep 28.

PMID:
27692902
16.

Clinical and pathologic features of families with LRRK2-associated Parkinson's disease.

Whaley NR, Uitti RJ, Dickson DW, Farrer MJ, Wszolek ZK.

J Neural Transm Suppl. 2006;(70):221-9. Review.

PMID:
17017533
17.

Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.

Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Maraganore DM, Czyzewski K, Styczynska M, Wszolek ZK, Farrer MJ, Toft M.

Am J Hum Genet. 2005 Apr;76(4):672-80. Epub 2005 Feb 22.

18.

LRRK2 mutations are a common cause of Parkinson's disease in Spain.

Mata IF, Ross OA, Kachergus J, Huerta C, Ribacoba R, Moris G, Blazquez M, Guisasola LM, Salvador C, Martinez C, Farrer M, Alvarez V.

Eur J Neurol. 2006 Apr;13(4):391-4.

PMID:
16643318
19.

The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.

Latourelle JC, Sun M, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Goldwurm S, Pezzoli G, Zini M, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Laramie JM, DeStefano AL, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH.

BMC Med. 2008 Nov 5;6:32. doi: 10.1186/1741-7015-6-32.

20.

LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.

Gaig C, Ezquerra M, Marti MJ, Muñoz E, Valldeoriola F, Tolosa E.

Arch Neurol. 2006 Mar;63(3):377-82.

PMID:
16533964

Supplemental Content

Support Center